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Abstract: When compared with the general population, the diabetic population is at higher 
risk of cardiovascular disease (CVD), as predicted by the Framingham Risk Score calculations 
(10-year risk 20%). For this reason diabetes is considered a “coronary disease equivalent” 
condition, as classified by the National Cholesterol Education Program Adult Treatment Panel 
(NCEP-ATP) III. Furthermore, patients with diabetes who experience a myocar  dial infarction 
have a poorer prognosis than non  diabetic patients, which contributes to their overall higher 
mortality. Dyslipidemia is a major underlying risk factor contributing to the excess CVD risk, 
and is usually more atherogenic in the presence of diabetes. It is uniquely manifested by raised 
levels of triglycer  ides, low levels of high-density lipoprotein cholesterol, and smaller, denser, 
and more atherogenic low-density lipoprotein particles. Recent trials have suggested the need 
for more aggressive treatment of dyslipidemia in this subpopulation than the current recommen-
dations by the NCEP-ATP III. This review addresses the newer developments in the diabetes 
arena in terms of our current understanding of atherogenic dyslipidemia in diabetes and data 
from the latest randomized trials addressing its management.
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Introduction
The World Health Organization (WHO) defines cardiovascular disease (CVD) as 
“A group of disorders of the heart and blood vessels and includes coronary heart disease, 
cerebrovascular disease, peripheral artery disease, rheumatic heart disease, congenital 
heart disease, deep vein thrombosis, and pulmonary embolism”. Furthermore, WHO 
estimates show that mortality from CVD accounts for 29% of all deaths worldwide.1 
In the US, death from CVD continues to be the leading cause of mortality.2 More specifi-
cally, coronary heart disease (CHD) is the largest component of death related to CVD, 
both worldwide and within the US.1,2 Risk factors for CVD, both major and minor, 
include high blood pressure, cigarette smoking, high serum cholesterol, low levels of 
high-density lipoprotein cholesterol (HDL-C), high levels of low-density lipoprotein 
cholesterol (LDL-C), diabetes, obesity (especially central obesity), left ventricular 
hypertrophy, family history of premature CVD, and estrogen replacement.3
Pathophysiology
CHD is caused by atherosclerosis, ie, hardening of an artery due to atheromatous 
plaque.4 The formation of an atheromatous plaque, known as atherogenesis, is a 
  complex process involving both cellular and acellular elements.5 Although there is a 
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in those processes, the attention of bench and clinical 
  researchers, the pharmaceutical industry, and   treatment 
providers has been focused on acellular elements for   several 
decades. The major acellular elements are cholesterol, 
  cholesterol esters, and phospholipids. Whereas the human 
body produces the   majority of its daily requirement of 
  cholesterol, most Americans now exceed that requirement 
with additional intake through their diet.
Because cholesterol is insoluble when it enters the 
  circulatory system it is transported as a lipoprotein. The major 
lipoprotein entities in a fasting individual are LDL-C, 
HDL-C, and very low-density lipoprotein cholesterol 
(VLDL-C). Measuring serum fasting lipid levels assists in 
evaluating and treating excessive serum lipid levels which 
are associated with increased morbidity and mortality from 
CHD. A fasting serum lipid panel consists of total cholesterol 
(TC), LDL-C, HDL-C, and triglyceride concentrations.
While each of the aforementioned parameters have been 
shown to be independent risk factors for developing CHD, 
further analysis has shown that the aim of treatment should 
be reduction of the concentration of LDL-C   particles because 
these are highly atherogenic and constitute 60%–70% of 
TC.6 In fact, the atherogenic nature of LDL-C, even when 
considered low-risk for developing CHD, has the potential 
to raise CHD risk, especially when combined with other 
elements. This overall combination, borderline high-risk 
LDL-C (130–159 mg/dL), high-normal triglycerides 
(150–250 mg/dL), presence of small LDL-C particles, and 
low HDL-C (,35 mg/dL) is what defines “atherogenic 
dyslipidemia”.7 However, as per the Third Report of the 
National Cholesterol Education Program – Adult Treatment 
Panel (NCEP-ATP) III, atherogenic dyslipidemia is defined 
as the triad of elevated triglycerides, low HDL-C, and small 
LDL-C particles. This triad is most commonly found in 
individuals with an atherogenic phenotype and/or type 2 
diabetes mellitus (DM), and treatment involves lowering 
triglycerides and increasing HDL-C by diet modification, 
increased exercise, and pharmacologic therapy with fibrates 
or nicotinic acid.6
Scope of the problem
The risk of developing atherosclerotic disease is increased 
two- to three-fold in people with diabetes.9 The WHO   estimate 
of worldwide diabetic prevalence of 171 million in 2000 is 
expected to grow substantially to 366 million by 2030.10 
In the US alone, the WHO estimates that the   prevalence will 
increase from 17,702,000 in 2000 to 30,312,000 by 2030.11 
For the year 2007, the Centers for Disease Control and 
Prevention estimates that the prevalence of diagnosed DM 
in individuals of all ages in the US was 23.6 million, which 
is close to the WHO 2030 estimate. DM is categorized as 
type 1, type 2, gestational, and other, with type 2 being the 
most frequently diagnosed category.12 In terms of financial 
costs, Haung and Basu et al projected that annual spending on 
DM over the next 25 years will grow to $336 billion per year, 
with Medicare slightly exceeding 50% of its total yearly 
expenditure on the disease by 2034.13 It is clear that aggres-
sive medical and financial management is needed for type 2 
DM and atherogenic dyslipidemia.
Management strategies
As evidenced by the Scandinavian Simvastatin Survival 
Study (4S),14 Cholesterol And Recurrent Events (CARE),15 
and Long-Term Intervention with Pravastatin in Ischemic 
Disease (LIPID)16 secondary prevention trials, as well as the 
primary and secondary trials Heart Protection Study (HPS),17 
  Antihypertensive and Lipid-Lowering   Treatment to prevent 
Heart Attack Trial (ALLHAT),18 and   Anglo-Scandinavian 
Cardiac Outcome Trial-Lipid Lowering Arm (ASCOT-LLA),19 
and the most recent and only primary prevention study, the Col-
laborative Atorvastatin Diabetes Study (CARDS),20 the use of 
statins in type 2 diabetics has been shown to decrease CVD out-
comes significantly (see Figure 1). Furthermore, a meta-analysis 
of 18,686 diabetics on a statin in the Cholesterol Treatment 
Trialists’ (CTT) collaborators study found that, after a mean 
follow-up of 4.3 years there was a proportional 9% decrease 
in all-cause mortality per mmol/L reduction in LDL-C, and a 
proportional 21% reduction per mmol/L decrease in LDL-C in 
major vascular events, compared with nondiabetics, indicating 
that all diabetics should start an HMG-CoA reductase inhibitor 
if they are at high risk for vascular events.36
This is consistent with current treatment recommendations 
from the NCEP-ATP III, which addresses the management 
of atherogenic dyslipidemia, and makes recommendations 
for weight reduction, increased exercise, and lipid-lowering 
therapies (ie, HMG-CoA reductase inhibitors, fibrates, and 
nicotinic acid).6 In terms of atherogenic dyslipidemia and DM, 
specifically those with type 2 DM, the NCEP-ATP III and the 
American Diabetes Association (ADA) both recommend life-
style modification and HMG-CoA reductase inhibitor therapy 
regardless of baseline LDL-C for those with overt CVD and 
those without CVD who are age .40 years with one or more 
CVD risk factors. For those who do not have overt CVD or 
age ,40 years, statin therapy should be considered, along with 
lifestyle modification if LDL-C is .100 mg/dL or the patient 
has multiple CVD risk factors. Treatment goals for LDL-C Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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are LDL-C ,100 mg/dL for those without overt CVD, and 
LDL-C ,70 mg/dL for those with overt CVD.6,21
Non-HDL-C (calculated as total cholesterol – HDL 
  cholesterol) is a secondary target for therapy in the   NCEP-ATP 
III recommendations. The ADA and the American College 
of Cardiology recommend that non-HDL-C target goals 
for diabetics with overt CVD should be ,130 mg/dL and 
apolipoprotein-B ,80 mg/dL. Those diabetics without overt 
CVD are recommended to have non-HDL-C ,130 mg/dL 
and apolipoprotein-B ,90 mg/dL.22 This is due to the fact 
that LDL-C is not usually raised in diabetics, thus leaving 
the components that make up non-HDL-C, especially in the 
presence of hypertriglyceridemia, more representative and 
a more reliable measure of atherogenicity, such that there is 
discussion to advance non-HDL-C as a better predictor of 
CVD in diabetics.6,23,35
Reaching both these current LDL-C and non-HDL-C 
targets raises the issues of dosage requirements for 
  lipid-lowering drugs, patient tolerability, and side effects 
either as single or combination treatment.24–26 Regardless, in 
the event that a single statin even at maximal dose is unable 
to achieve recommended goals, an alternative therapeutic 
goal is to lower LDL-C by approximately 30%–40% of the 
baseline value. Should that prove unattainable, consideration 
should be given to treatment with a combination of medica-
tion classes (ie, statin + fibrate).6,21 As aforementioned, should 
the patient also be at high risk for developing vascular events, 
starting an HMG-CoA reductase inhibitor is beneficial, whilst 
considering the risks and side effects. Another avenue of 
diabetic lipid management involves the emerging science 
behind combining pharmacology and gene regulation.
Newer findings
Researchers studying adipose tissue as an endocrine organ 
have identified a number of lipid metabolism regulators. 
The peroxisome proliferator-activated receptor (PPAR) is a 
Study Intervention  CVD outcome  RRR diabetes % 
Primary prevention 
CARDS Atorvastatin 10 mg  Acute coronary events 
CVA
36
48
HPS 
Simvastatin 40 mg  Major CHD event 
Any major CV Event 
27 
22 
ALLHAT Pravastatin 10 mg  Major CHD event  11
ASCOT-LLA Atorvastatin 10 mg  Major CHD event 
Total CV events and 
procedures
16
23
Secondary prevention 
4S Simvastatin 10–40 mg  Total mortality 
Major CHD event 
43
55
CARE Pravastatin 40 mg  Major CHD event 
Expanded endpoint 
13
25
LIPID Pravastatin 40 mg   Major CHD event 
Any CV event 
19
21
Primary and secondary 
prevention
Figure 1 effect of primary and secondary interventions for type 2 diabetics on CVD outcome. 
Notes: Copyright © 2006. American Diabetes Association. All rights reserved. Modified with permission from The American Diabetes Association from Solano MP, Goldberg RB. 
Lipid management from type 2 diabetes. Clin Diabetes. 2006;24(1):27–32.
Abbreviations: 4S, Scandinavian Simvastatin Survival Study; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial; ASCOT-LLA, Anglo-
Scandinavian Cardiac Outcome Trial – Lipid Lowering Arm; RRR, relative risk reduction; CARDS, Collaborative Atorvastatin Diabetes Study; CARe, Cholesterol And 
Recurrent events; CHD, coronary heart disease; CV, cardiovascular; CVA, cerebrovascular accident; LiPiD, Long-Term intervention with Pravastatin in ischemic Disease.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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nuclear receptor that, when activated, works at the genetic 
level by regulating lipid and glucose metabolism as well as 
inflammation.26 There are three types of PPARs, ie, PPARα, 
PPARγ, and PPARδ, all of which are found in organs 
throughout the body. Fibric acid derivatives (ie, gemfibrozil 
and fenofibrate) have been used in the treatment of 
hyperlipidemia. They have also been shown to produce their 
effects through PPARα.26–29 It should be noted that in the 
Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD) study that, compared with placebo, fenofibrates 
failed to reach statistical significance in reducing the primary 
study outcome, ie, CHD or nonfatal myocardial infarction, 
but did show a statistically significant reduction in total 
cardiovascular events. However there are questions related 
to the use of statins in the placebo arm.37
Thiazolidinediones, which are oral antidiabetic agents, 
also activate PPARγ and thereby increase adiponectin 
levels.26,33 Increasing adiponectin levels has been shown in 
animal trials to reduce weight in mice given high-fat diets.30 
Furthermore, adiponectin has been shown to activate the 
adenosine monophosphate-protein kinase (AMPK) cascade 
which regulates energy homeostasis in the body.31 The 
AMPK cascade is also a target for metformin, another oral 
antidiabetic medication.32 Despite these advances in knowl-
edge about the pathophysiology of diabetes, translating this 
knowledge into clinical practice has been difficult due to 
drug side effects and increased morbidity.26,33
It is also worth mentioning that the recent Bypass Angio-
plasty Investigation 2 Diabetes (BARI 2D) study found that 
in 2368 type 2 diabetic patients with heart disease, those with 
stable ischemic heart disease who received optimal medical 
management showed no significant disadvantage in terms 
of the primary endpoint of death or the composite endpoint 
of death, myocardial infarction, or stroke, compared with 
those undergoing prompt revascularization only or those 
with stable ischemic heart disease who underwent delayed 
revascularization.34 These findings have strong implications 
with respect to cardiac revascularization in type 2 diabetics. 
However, in terms of primary care, this study shows that 
optimal medical management of a patient with type 2 diabetes 
has significant cost benefits without increasing morbidity 
or mortality, and may become the standard of care in this 
patient population.
Conclusions
In summary, the current status, associated cardiovascular 
risk, expected increase in prevalence, and projected monetary 
costs associated with DM and atherogenic dyslipidemia are 
well documented, along with the long-term cardiovascular 
morbidity and mortality risk. Despite ongoing research, tech-
nologic advances, and newer medications that work increas-
ingly at the genetic level, the best and most cost-effective 
treatment remains prevention. Preventing the development 
of type 2 DM and its associated cardiometabolic disturbance 
involves early adoption of a healthy lifestyle that incorporates 
diet modification, increased exercise, and regular health care 
maintenance visits with a primary care physician. Once diag-
nosed, the management involves decreasing the atherogenic 
components by adherence to the NCEP-ATP III and ADA 
recommendations, so that the patient and the health system 
may forestall the ensuing cardiovascular morbidity and mor-
tality, as well as its associated financial burden.
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